Niraparib Shrinks BRCA-Mutated Prostate Tumors

    Cancer Discovery
    |March 3, 2019
    PubMed

    Insights

    Niraparib demonstrates efficacy in advanced prostate cancer patients with DNA damage-response pathway mutations. The drug is particularly effective in men with BRCA1 or BRCA2 gene defects.

    Area of Science:

    • Oncology
    • Genetics
    • Pharmacology

    Background:

    • The GALAHAD trial investigated niraparib in men with advanced prostate cancer.
    • Patients had tumors with mutations in the DNA damage-response (DDR) pathway.

    Discussion:

    • Niraparib, a PARP inhibitor, targets DNA repair mechanisms.
    • Tumor mutations in DDR genes, including BRCA1/2, confer sensitivity to PARP inhibitors.

    Key Insights:

    • Niraparib showed promising efficacy in this patient population.
    • Efficacy was most pronounced in patients with BRCA1 or BRCA2 gene mutations.

    Outlook:

    • Further research may establish niraparib as a treatment option for specific prostate cancer subtypes.
    • Genomic profiling can identify patients likely to benefit from niraparib therapy.

    Related Concept Videos

    Mutations01:39

    Mutations

    Overview
    94.4K
    Mutations01:35

    Mutations

    Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
    Chromosomal Alterations Are Large-Scale Mutations
    While point mutations are changes in a single nucleotide in...
    44.5K
    Viral Mutations00:36

    Viral Mutations

    A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
    39.9K
    Mutation, Gene Flow, and Genetic Drift01:09

    Mutation, Gene Flow, and Genetic Drift

    In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
    64.0K
    Mutations in Microorganisms01:18

    Mutations in Microorganisms

    Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
    717
    Point and Frameshift Mutations01:30

    Point and Frameshift Mutations

    Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
    1.1K